Biogen to pay $1.25bn to Forward Pharma in licensing deal

Biogen and Forward Pharma, a Denmark-based company, have entered into a settlement and licensing agreement under which Biogen will pay Forward Pharma $1.25 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Biogen asks district court to dismiss competition complaint by Ixchel

26 May 2017 Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.

Americas

Forward Pharma files opening brief against PTAB Biogen decision

7 September 2017 Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).

Big Pharma

Biogen fights off Mylan’s Tecfidera patent challenge

6 February 2020 US multinational biotechnology company Biogen has successfully defended multiple sclerosis treatment Tecfidera from a patent challenge brought by generic and specialty pharma company Mylan.

More on this story

Americas

Biogen asks district court to dismiss competition complaint by Ixchel

26 May 2017 Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.

Americas

Forward Pharma files opening brief against PTAB Biogen decision

7 September 2017 Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).

Big Pharma

Biogen fights off Mylan’s Tecfidera patent challenge

More on this story

Americas

Biogen asks district court to dismiss competition complaint by Ixchel

26 May 2017 Biogen has asked the US District Court for the Eastern District of California to dismiss a competition complaint filed by biotech company Ixchel Pharma.

Americas

Forward Pharma files opening brief against PTAB Biogen decision

7 September 2017 Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).

Big Pharma

Biogen fights off Mylan’s Tecfidera patent challenge